관절 조직과 상처에서 분리된 Vancomycin-intermediate Staphylococcus aureus 2예
Two Cases of Vancomycin-intermediate Staphylococcus aureus Isolated from Joint Tissue or Wound
2
조회
0
다운로드
3
인용
0
참고문헌
초록
Abstract
Since its first isolation in 1997, vancomycin-intermediate Staphylococcus aureus (VISA) has been a clinical concern because it may lead to treatment failure. Up to the present, there were two reports of clinical VISA cases in Korea. We now report two additional cases of VISA with the minimum inhibitory concentration (MIC) of 4 μg/mL. The first patient was a 59 yr-old man who had undergone total hip replacement arthroplasty in 1999 due to avascular necrosis of femur heads. He had recurrent episodes of infected hip caused by methicillin-resistant Staphylococcus aureus (MRSA) and was treated with vancomycin. He underwent replacement operation of prosthesis. Cultures of joint fluid and joint tissue grew S. aureus. Vancomycin MIC as determined by a broth microdilution method was 4 μg/mL for the both isolates. The patient was treated with high enough doses of vancomycin to maintain serum trough concentrations at 20-25 μg/mL for 52 days and was discharged. The second patient was a 57 yr-old man with diabetes. He lost consciousness from drinking. After recovery of consciousness, he was diagnosed with aspiration pneumonia. MRSA and Acinetobacter baumannii were cultured from sputum and the patient was treated with vancomycin and meropenem. During hospitalization, bed sores developed in his ankle and back. A wound culture from the sore grew S. aureus with vancomycin MIC of 4 μg/mL. Since infection was localized, systemic antibiotics did not seem necessary, and the patient was transferred to another hospital for isolation and management. (Korean J Lab Med 2008;28:444-8)
참고문헌 (14)
- Hidayat LK, "Highdose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity", Arch Intern Med, 166, pp.2138~2144 (2006)
- Clinical and Laboratory Standards Institute, "Performance standards for antimicrobial susceptibility testing; Sixteenth Informational Supplemen" (2006), Clinical and Laboratory Standards Institute
- Kim MN, "Vancomycin-intermediate Staphylococcus aureus in Korea", J Clin Microbiol, 38, pp.3879~3881 (2000)
- Kim HB, "Preva lence and clinical implications of Staphylococcus aureus with a vancomycin MIC of 4 microg", ml in Korea, 2006, pp.12, 33~38
- Clinical and Laboratory Standards Institute, "Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard-Seventh Edition" (2006), Clinical and Laboratory Standards Institute
- Chang S, "Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene", N Engl J Med, 348, pp.1342~1347 (2003)
- ugen M, "Network on Antimicrobial Resistance in Staphylococcus aureus (NARSA). http:", (Updated on Jul 2008), 2008[DOI]
- Appelbaum PC., "The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus", Clin Microbiol Infect, 12(S), pp.S16~S23 (2006)
- Hiramatsu K., "Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance", Lancet Infect Dis, 1, pp.147~155 (2001)
- Gemmell CG, "Guidelines for the prophylaxis and treatment of methicillinresistant Staphylococcus aureus (MRSA) infections in the UK", J Antimicrob Chemother, 57, pp.589~608 (2006)
- Drew RH., "Emerging options for treatment of invasive, multidrugresistant Staphylococcus aureus infections", Pharmacotherapy, 27, pp.227~249 (2007)
- Ruef C., "Epidemiology and clinical impact of glycopeptide resistance in Staphylococcus aureus", Infection, 32, pp.315~327 (2004)
- [URL]
- Tenover FC, "Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides", J Clin Microbiol, 36, pp.1020~1027 (1998)